The emerging role of hormonal ablation as adjuvant therapy in node + and node – pre-/perimenopausal patients
- 1 August 2001
- journal article
- Published by Elsevier in The Breast
- Vol. 10, 123-129
- https://doi.org/10.1016/s0960-9776(16)30021-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93The Breast, 2001
- Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized TrialJournal of Clinical Oncology, 2000
- Systemic adjuvant treatment for premenopausal node-negative breast cancerEuropean Journal Of Cancer, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopauseCancer, 1998
- New endocrine approaches in the treatment of breast cancerBiomedicine & Pharmacotherapy, 1998
- Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.Journal of Clinical Oncology, 1998
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.Journal of Clinical Oncology, 1989